0001415889-22-012992.txt : 20221227 0001415889-22-012992.hdr.sgml : 20221227 20221227171601 ACCESSION NUMBER: 0001415889-22-012992 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220520 FILED AS OF DATE: 20221227 DATE AS OF CHANGE: 20221227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wingrove Theresa CENTRAL INDEX KEY: 0001510720 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 221491040 MAIL ADDRESS: STREET 1: IMMUNOGEN, INC. STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoGen, Inc. CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGEN INC DATE OF NAME CHANGE: 19920703 4 1 form4-12272022_101249.xml X0306 4 2022-05-20 0000855654 ImmunoGen, Inc. IMGN 0001510720 Wingrove Theresa C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM MA 02451 false true false false SVP OF REGULATORY AFFAIRS Stock Option (Right to Buy) 4.55 2022-05-20 4 A 0 83363 0 A 2022-05-20 2030-02-07 Common Stock 83363 83363 D Stock Option (Right to Buy) 4.55 2022-11-14 4 A 0 166725 0 A 2022-11-14 2030-02-07 Common Stock 166725 250088 D On February 7, 2020, the reporting person was granted an option to purchase 333,450 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award. On February 7, 2020, the reporting person was granted an option to purchase 333,450 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award. /s/ Renee Lentini, Attorney-in-Fact 2022-12-27